To estimate whether inhibiting tumor cell stemness transformation improves the efficacy of ICB on TNBC, we established the anti‐PD‐1 therapy resistance mouse model as described previously.[19] Then, the mice were injected with Rosc (2 mg kg−1) or anti‐PD‐1 antibody (100 μg per mouse), individually or in combination, on days 7, 12, 17, and 22 (Figure 7A, top). The gene discussed is PDCD1; the disease is neoplasm.